Gilteritinib for Acute Myeloid Leukaemia (AML)

Gilteritinib (Xospata, Astellas Pharma Europe B.V) is a highly specific, second-generation tyrosine kinase inhibitor which has been developed for the treatment of patients with acute myeloid leukaemia (AML) who have an FMS-like tyrosine kinase 3 (FLT3) mutation.

Please note - this is a digital download only and you will not receive a hardcopy through the post. 

Digital downloads

To access an instant download of our Gilteritinib for Acute myeloid leukaemia (AML) information booklet, please click here (opens as a PDF file). 

Each booklet takes us approximately six months to write and is supplied free of charge to patients, families and hospitals across the UK. It costs us approximately £3 to provide one booklet. Please consider adding a donation to your order if you can.